These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 14970368)
1. Once-daily cefazolin and probenecid for skin and soft tissue infections. Cox VC; Zed PJ Ann Pharmacother; 2004 Mar; 38(3):458-63. PubMed ID: 14970368 [TBL] [Abstract][Full Text] [Related]
2. Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. Grayson ML; McDonald M; Gibson K; Athan E; Munckhof WJ; Paull P; Chambers F Clin Infect Dis; 2002 Jun; 34(11):1440-8. PubMed ID: 12015689 [TBL] [Abstract][Full Text] [Related]
3. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. Bradsher RW; Snow RM Am J Med; 1984 Oct; 77(4C):63-7. PubMed ID: 6093522 [TBL] [Abstract][Full Text] [Related]
4. Intravenous cefazolin plus oral probenecid versus oral cephalexin for the treatment of skin and soft tissue infections: a double-blind, non-inferiority, randomised controlled trial. Dalen D; Fry A; Campbell SG; Eppler J; Zed PJ Emerg Med J; 2018 Aug; 35(8):492-498. PubMed ID: 29914924 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Stein GE; Schooley SL; Peloquin CA; Kak V; Havlichek DH; Citron DM; Tyrrell KL; Goldstein EJ Ann Pharmacother; 2005 Mar; 39(3):427-32. PubMed ID: 15701775 [TBL] [Abstract][Full Text] [Related]
6. Risk factors of cellulitis treatment failure with once-daily intravenous cefazolin plus oral probenecid. Bader MS; Twells L; Hawboldt J South Med J; 2011 Dec; 104(12):789-93. PubMed ID: 22089355 [TBL] [Abstract][Full Text] [Related]
7. Management of cellulitis in a pediatric emergency department. Khangura S; Wallace J; Kissoon N; Kodeeswaran T Pediatr Emerg Care; 2007 Nov; 23(11):805-11. PubMed ID: 18007211 [TBL] [Abstract][Full Text] [Related]
8. Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections. Brown G; Chamberlain R; Goulding J; Clarke A J Emerg Med; 1996; 14(5):547-51. PubMed ID: 8933313 [TBL] [Abstract][Full Text] [Related]
9. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Seltzer E; Dorr MB; Goldstein BP; Perry M; Dowell JA; Henkel T; Clin Infect Dis; 2003 Nov; 37(10):1298-303. PubMed ID: 14583862 [TBL] [Abstract][Full Text] [Related]
11. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. McKinnon PS; Sorensen SV; Liu LZ; Itani KM Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705 [TBL] [Abstract][Full Text] [Related]
12. Dalbavancin: a novel lipoglycopeptide antibacterial. Pope SD; Roecker AM Pharmacotherapy; 2006 Jul; 26(7):908-18. PubMed ID: 16803423 [TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Arbeit RD; Maki D; Tally FP; Campanaro E; Eisenstein BI; Clin Infect Dis; 2004 Jun; 38(12):1673-81. PubMed ID: 15227611 [TBL] [Abstract][Full Text] [Related]
14. Daptomycin: rationale and role in the management of skin and soft tissue infections. Seaton RA J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721 [TBL] [Abstract][Full Text] [Related]
15. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Sharpe JN; Shively EH; Polk HC Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454 [TBL] [Abstract][Full Text] [Related]
16. [Cefditoren pivoxil: A new oral cephalosporin for skin, soft tissue and respiratory tract infections]. Hernández-Martin J; Romá E; Salavert M; Doménech L; Poveda JL Rev Esp Quimioter; 2006 Sep; 19(3):231-46. PubMed ID: 17099791 [TBL] [Abstract][Full Text] [Related]
17. Dalbavancin: a new option for the treatment of gram-positive infections. Lin SW; Carver PL; DePestel DD Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624 [TBL] [Abstract][Full Text] [Related]
18. Oral antibiotic treatment for methicillin-resistant Staphylococcus aureus skin and soft tissue infections: review of the literature. Khawcharoenporn T; Alan T Hawaii Med J; 2006 Oct; 65(10):290-3. PubMed ID: 17194061 [TBL] [Abstract][Full Text] [Related]
19. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045 [TBL] [Abstract][Full Text] [Related]
20. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Davis SL; McKinnon PS; Hall LM; Delgado G; Rose W; Wilson RF; Rybak MJ Pharmacotherapy; 2007 Dec; 27(12):1611-8. PubMed ID: 18041881 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]